H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Halozyme to $60 from $61 and keeps a Buy rating on the shares post the Q2 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
